meta|Evidence - COVID-19
click on circles to display study description...
umifenovir (arbidol) (n=16) vs. standard of care (n=7)
randomized controlled trial some concerns about risk of bias
arbidol
arbidol (100mg) (oral, 200mg TID for 7-14 days)
standard care
3 arms : lopinavir/ritonavir; arbidol and standard care
COVID 19 all comers
open-label
China, single center
umifenovir (arbidol) (n=50) vs. lopinavir/ritonavir (n=50)
randomized controlled trial some concerns about risk of bias
Arbidol (umifenovir)
Hydroxychloroquine (400 mg BD on first day followed by 200 mg BD) followed by ARB (200 mg TDS) 7 to 14 days based on the severity of disease.
Lopinavir-ritonavir (Kaletra)
Hydroxychloroquine (400 mg just on first day) followed by 400 mg Kaletra (Lopinavir-ritonavir) BD
HCQ in both groups. Arbidol 100mg caps.
COVID 19 hospitalized
Open-label
single center, teaching hospital of Iran University of medical Sciences (IUMS), Tehran, Iran.
The criteria of improvement were relief of cough, dyspnea and fever.
umifenovir (arbidol) (n=35) vs. lopinavir/ritonavir (n=34)
randomized controlled trial some concerns about risk of bias
Umifenovir
Arbidol (100mg) (oral, 200mg TID for 7-14 days)
Lopinavir/ritonavir
Lopinavir (200mg) boosted by ritonavir (50mg) (orally administed, twice daily, 500 mg, each time for 7-14 days).
3 arms : lopinavir/ritonavir; arbidol and standard care
COVID-19 mild to moderate
Open-label
China, single center
No deaths occurred.
umifenovir (arbidol) (n=15) vs. standard of care (n=15)
randomized controlled trial high risk of bias
Umifenovir
600mg/d: orally administered, 200 mg three times per day for 1–5 days
Standard of care
Antivirals, antibiotics, immunoglobulin, and corticosteroids.
Standard of care in both groups.
COVID-19 mild to moderate
Age: 18-60
Not specified.
Single center, City Clinical Hospital in Bishkek, Kyrgyzstan.
Blindness unclear.
powered by vis.js Network